· investment-strategies · 2 min read
Biotech & Healthtech Funding May–June 2026: ADCs, Immune Mapping, and AI Care
Anagram Therapeutics, Ona Therapeutics, IMU Biosciences, and Garner Health show biotech and healthtech capital in 2026 favoring validated science and AI-enabled care.
Biotech and healthtech in May–June 2026 followed the same discipline reshaping the rest of venture: fund validated science and measurable outcomes, not platform promises. The winners pair real clinical data with credible commercial paths.
The deal sheet
| Company | Region | Amount | Focus |
|---|---|---|---|
| Anagram Therapeutics | U.S. | $250M | Therapeutics |
| Garner Health | U.S. | $100M Series E | Healthcare data ($2.74B val) |
| Ona Therapeutics | Spain | $86.6M Series B | Antibody-drug conjugates |
| IMU Biosciences | UK | $53M+ Series A | Immune-system mapping |
| Semble | UK | £30M Series C | Health tech |
Three themes
- Hard science is fundable. Ona Therapeutics’ oversubscribed $86.6M targets first-in-class ADCs for treatment-resistant cancers — exactly the validated, differentiated science investors will still pay for.
- Data infrastructure for care. Garner Health’s $100M Series E (Index Ventures, $2.74B valuation) backs a provider-finding platform — healthcare data as a durable, defensible layer.
- AI plus clinical rigor. IMU Biosciences’ immune-decoding platform and Europe’s health-tech rounds (Semble) reflect demand for tools that improve outcomes or reduce cost with measurable evidence.
The discipline that defines the cohort
Across geographies, the fundable healthcare company shows clinical validation, regulatory pathways, or cost evidence — not generic wellness. Capital is patient but selective, rewarding depth.
Practical takeaway (operator + investor)
Healthcare founders should lead with clinical or economic proof — trial data, abstraction accuracy, or cost savings. For investors, the durable opportunities sit in validated therapeutics, care-delivery data infrastructure, and AI tools with demonstrated outcomes.
Sources
- PipelineRoad / Crunchbase (Anagram Therapeutics $250M): https://pipelineroad.com/news/20260508-top-10-biggest-funding-rounds-this-week-in-ai-and-tech
- Crunchbase News (Garner Health $100M Series E): https://news.crunchbase.com/ai/biggest-funding-rounds-ai-anthropic-65b-dominates/
- Startuprise (Ona Therapeutics, IMU Biosciences, Semble): https://startuprise.co.uk/top-funding-wrap-of-the-week-01-june-05-june-2026/